Home » Posts tagged with » Cosela
G1 Therapeutics gets Cosela FDA approval to reduce chemotherapy-induced bone marrow suppression

G1 Therapeutics gets Cosela FDA approval to reduce chemotherapy-induced bone marrow suppression

G1 Therapeutics has bagged approval for Cosela (trilaciclib) from the US Food and Drug Administration (FDA) for reducing bone marrow suppression caused by chemotherapy. Cosela FDA approval is for its use in cutting down the frequency of chemotherapy-induced bone marrow suppression in adults who are undergoing certain types of chemotherapy for extensive-stage small cell lung […]